Concepedia

Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?

Meghan E. Daigle, Lisa G. Suter, David J. Hunter, Daniel H. Solomon, Rochelle P. Walensky, J.M. Jordan, Sara A. Burbine, A. David Paltiel, Jeffrey N. Katz

Osteoarthritis and Cartilage · 2013 · 64 citations · 43 references

DOIFull text

Open access

Concepts

References

43

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II

Reva C. Lawrence, David T. Felson, Charles G. Helmick et al. · Arthritis & Rheumatism · 2007 · 5.5K citations

, , +9

Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis

Fred E. Silverstein, Gerald A. Faich, Jay L. Goldstein et al. · JAMA · 2000 · 3.2K citations

, , +16

Body-Mass Index and Mortality among 1.46 Million White Adults

Amy Berrington de González, Patricia Hartge, James R. Cerhan et al. · New England Journal of Medicine · 2010 · 2.3K citations · Full text

, , +10

Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention

Scott D. Solomon, John J.V. McMurray, Marc A. Pfeffer et al. · New England Journal of Medicine · 2005 · 2.1K citations · Full text

, , +13

Recommendations for Reporting Cost-effectiveness Analyses

Joanna E. Siegel · JAMA · 1996 · 1.2K citations

, , +10